AbbVie shares tank on Rova-T flop, sudden retreat from accelerated approval pitch

AbbVies stock $ABBV is getting hammered this morning after its $10 billion Rova-T program posted poor mid-stage results for third-line small cell lung cancer, forcing the company to scuttle any plans to seek an accelerated approval for the closely-watched drug after talks with skeptical regulators.

• Source: 4-traders
• 611
• March 26, 2018